Please login to the form below

Not currently logged in
Email:
Password:

Zulresso

This page shows the latest Zulresso news and features for those working in and with pharma, biotech and healthcare.

Sage slides off a MOUNTAIN as depression drug flunks trial

Sage slides off a MOUNTAIN as depression drug flunks trial

SAGE-217 is an oral follow-up to Sage’s  Zulresso (brexanolone) for postpartum depression (PPD), which was approved by the FDA in March and is delivered by a ... With analysts suggesting that Zulresso’s high cost ($34, 000 at US list price) and

Latest news

More from news
Approximately 3 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Life Healthcare Communications

Life is a creative communications agency offering multi-channel solutions for the healthcare industry. We use a storytelling approach to turn...

Latest intelligence

Diversity in clinical trials: looking back at our 2021 blogs
In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
Webinar:
Securing a future for telehealth with immersive market research insights...